The products involved in the collaboration center around the treatment of cardiac arrhythmias in markets that include Europe and Asia, according to a news release.
The partnership centers on Acutus’ AcQMap system, which Acutus touts as the only commercially available non-contact mapping system that can map stable and unstable rhythms. Those capabilities enable electrophysiologists to see changes in conduction during a procedure, giving them a basis on which to customize therapy, according to the company.
Under the agreement, Acutus expects to market a range of Biotronik EP ablation catheters and diagnostic/accessory products under a private label to most international markets. The companies believe they can create a secure digital network across cardiac rhythm management and electrophysiology mapping and ablation devices.
“Healthcare systems around the world are facing continuous pressure to provide more targeted care for patients with better outcomes and reduced costs,” Acutus president & CEO Vince Burgess said in the news release. “We are at the forefront of equipping electrophysiologists with the technology they need to deliver advanced and individualized ablation therapy – more efficiently. We believe this international alliance has the potential to vault Acutus to the forefront of this important market.”
“As arrhythmias become more common, unprecedented access to real-time data will be integral to improving diagnosis and care,” added Biotronik segment head for EP & sensors Dr. Hans-Juergen Wildau. “We believe pairing Biotronik’s cardiac monitoring portfolio with Acutus’ innovative mapping technology will give EP specialists the edge in therapy guidance systems.”